Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.37 |
| ▸ | MTOR | P42345 | 5/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
| ▸ | GCKR | Q14397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994806 | 0.94 | HRH3 (0.39) | HRH3PIK3CAMTORGCKGCKR | |
| SCHEMBL1991781 | 0.91 | CHRNB2 (0.37) | HRH3PIK3CAMTORCHRNB2CHRNA4 | |
| SCHEMBL25243349 | 0.85 | MAPT (0.38) | HRH3MCHR1ACACB | |
| SCHEMBL25243350 | 0.85 | MAPT (0.38) | HRH3MCHR1ACACB | |
| SCHEMBL1977586 | 0.85 | CHRNB2 (0.48) | HRH3CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1977584 | 0.85 | CHRNB2 (0.48) | HRH3CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1979952 | 0.85 | CHRNB2 (0.48) | HRH3CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2792128 | 0.81 | PIK3CA (0.49) | HRH3PIK3CAMTORMCHR1CHRNB2 | |
| SCHEMBL18291701 | 0.81 | HRH3 (0.35) | HRH3PIK3CAMTORMCHR1CHRNB2 | |
| SCHEMBL18291482 | 0.81 | HRH3 (0.35) | HRH3PIK3CAMTORMCHR1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | HRH3 2304/4885PIK3CA 108/4885MTOR 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.